Literature DB >> 25294287

A decreased serum omentin-1 level may be an independent risk factor for peripheral arterial disease.

I Onur1, F Oz, S Yildiz, H Kuplay, C Yucel, S Sigirci, A Elitok, S Pilten, K Kasali, A Yasar Cizgici, V Erentug, H M Dinckal.   

Abstract

AIM: Recent evidence suggests that omentin-1, a visceral adipose-derived cytokine, may play a role in atherosclerosis The aim of this study was to evaluate whether serum omentin-1 levels are associated with peripheral artery disease (PAD) and its severity.
METHODS: The present study was cross-sectional and observational. We enrolled 123 patients with PAD and 50 age-matched subjects without PAD. The cardiovascular risk factors, ankle-brachial index (ABI), and serum omentin-1 levels were assessed in all participants
RESULTS: Patients with PAD had significantly lower omentin-1 levels than those without PAD (206. ±48.4 vs. 345. ±80 ng/mL, respectively; 0.001). A correlation analysis revealed positive correlations between the omentin-1 level and the ABI ( 0.52, P=0.008). After adjusting for cardiovascular risk factors, a decreased omentin-1 level was found to be an independent predictor of both PAD and its severity as measured by ABI in multivariate logistic regression analysis.
CONCLUSION: The current study suggests a strong association between decreased serum omentin-1 levels and PAD and its severity. Thus, omentin-1 may be a novel biomarker for PAD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25294287

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  6 in total

1.  Association between Circulating Omentin-1 Levels and Aortic Valve Sclerosis.

Authors:  Mustafa Dogdus; Ferhat Dindas; Yusuf Cekici; Arafat Yildirim; Mehmet Kucukosmanoglu; Nermin Yildiz Koyunsever; Ozge Ozcan Abacioglu; Salih Kilic
Journal:  Acta Cardiol Sin       Date:  2022-09       Impact factor: 1.800

2.  Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease.

Authors:  Federico Biscetti; Elisabetta Nardella; Nicola Bonadia; Flavia Angelini; Dario Pitocco; Angelo Santoliquido; Marco Filipponi; Raffaele Landolfi; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2019-06-05       Impact factor: 9.951

3.  Serum omentin-1 levels in hypertensive patients.

Authors:  Mustafa Çelik; Rukiye Nar; Gökay Nar; Erdoğan Sökmen; Güven Günver
Journal:  J Hum Hypertens       Date:  2020-09-25       Impact factor: 3.012

Review 4.  Association between Omentin-1 and Coronary Artery Disease: Pathogenesis and Clinical Research.

Authors:  Lutfu Askin; Hakan Duman; Ali Ozyıldız; Okan Tanriverdi; Serdar Turkmen
Journal:  Curr Cardiol Rev       Date:  2020

Review 5.  Adipokines and Inflammation: Focus on Cardiovascular Diseases.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Sandra Moraña-Fernández; Laura Anido-Varela; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Isabel Moscoso; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

Review 6.  The Role of Anti-Inflammatory Adipokines in Cardiometabolic Disorders: Moving beyond Adiponectin.

Authors:  Han Na Jung; Chang Hee Jung
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.